SCHEMBL3983751

SCHEMBL3983751

CC(C)CN(Cc1cccc(F)c1)C(Cc1cc(Cl)cc(Cl)c1)c1ncc[nH]1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.39
SLC6A3 Q01959 2/20 0.39
TAAR1 Q96RJ0 3/20 0.37
TSHR P16473 1/20 0.35
RECQL P46063 1/20 0.35
F2RL1 P55085 3/20 0.32
RORC P51449 1/20 0.32
BACE1 P56817 1/20 0.32
MAOA P21397 2/20 0.32
MAOB P27338 2/20 0.32
ACHE P22303 1/20 0.32
PNMT P11086 1/20 0.32
PPARG P37231 2/20 0.31
PPARA Q07869 2/20 0.31
OPRM1 P35372 1/20 0.31
OPRL1 P41146 1/20 0.31
KDM4E B2RXH2 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3978853 0.88 TAAR1 (0.38) TAAR1TSHRRECQLF2RL1PPARG
SCHEMBL3979787 0.86 TAAR1 (0.38) SLC6A2SLC6A3TAAR1F2RL1
SCHEMBL3980103 0.84 PKM (0.40) PPARGPPARAOPRM1OPRL1
SCHEMBL3978719 0.84 PPARG (0.36) TAAR1BACE1MAOAMAOBPPARG
SCHEMBL3981176 0.83 PPARG (0.36) TAAR1BACE1MAOAMAOBPPARG
SCHEMBL3984838 0.83 PPARG (0.35) BACE1MAOAMAOBPPARGPPARA
SCHEMBL3983790 0.83 OPRM1 (0.37) BACE1PPARGPPARAOPRM1OPRL1
SCHEMBL3979520 0.82 PSEN1 (0.37) SLC6A2SLC6A3F2RL1
SCHEMBL3981755 0.81 OPRM1 (0.38) BACE1PPARGPPARAOPRM1OPRL1
SCHEMBL3982294 0.81 CCNT1 (0.38) SLC6A2SLC6A3MAOBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572921-B2 Substituted benzylimidazoles useful for the treatment of inflammatory diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-08-11 US claimed
EP-1869012-A1 SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-12-26 EP claimed
US-20060252811-A1 SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-11-09 US claimed
WO-2006107923-A1 SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-10-12 WO claimed
US-7572921-B2 Substituted benzylimidazoles useful for the treatment of inflammatory diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-08-11 US disclosed
US-20060252811-A1 SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252811-A1 SUBSTITUTED BENZYLIMIDAZOLES USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASES IL4I1, NFKBIA, BRD4 SLC6A2 4578/4885SLC6A3 4734/4885TAAR1 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.